Arvind K. Shah

发表

Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

B. Abramson, P. Benlian, M. Hanson, 2011, Lipids in Health and Disease.

Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.

C. Ballantyne, T. Pearson, E. Veltri, 2009, The American journal of cardiology.

Bayesian Inference for Multivariate Meta-Regression With a Partially Observed Within-Study Sample Covariance Matrix

J. Ibrahim, Ming-Hui Chen, Sungduk Kim, 2015, Journal of the American Statistical Association.

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

Arvind Shah, Terje R Pedersen, K. Pyörälä, 2004, Diabetes care.

Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy.

J. Tomassini, J. Foody, W. Brown, 2010, Journal of clinical lipidology.

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.

Jennifer G. Robinson, W. Hsueh, J. Robinson, 2013, Journal of clinical lipidology.

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from th

Jennifer G. Robinson, W. Hsueh, J. Robinson, 2011, Journal of clinical lipidology.

Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.

M. Viigimaa, L. Missault, P. Brudi, 2011, Clinical biochemistry.

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

M. Viigimaa, L. Missault, P. Brudi, 2010, Lipids in Health and Disease.

Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.

P. Brudi, M. Farnier, Q. Dong, 2011, Journal of clinical lipidology.

Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity

M. Viigimaa, L. Missault, P. Brudi, 2011 .

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome

M. Viigimaa, L. Missault, P. Brudi, 2011, Diabetes & vascular disease research.

The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years

N. Wenger, O. Ben‐Yehuda, C. Jones-Burton, 2011, Journal of geriatric cardiology : JGC.

Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone

S. Kaplan, A. Johnson‐Levonas, Jianxin Lin, 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.

Bayesian inference for network meta-regression using multivariate random effects with applications to cholesterol lowering drugs.

J. Ibrahim, Ming-Hui Chen, Hao Li, 2019, Biostatistics.

Response to Boonen et al. ‘Assessing the relative efficacy of different osteoporosis agents based on the outcomes from meta‐analyses’

P. Geusens, M. Hochberg, P. Ross, 2007 .

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

P. Brudi, M. Farnier, Q. Dong, 2011, Lipids in Health and Disease.

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.

J. Paolini, H. Bays, D. Maccubbin, 2010, Journal of clinical lipidology.

Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis

Qing Tian, Jin Yang, T. Hong, 2020, Diabetes Therapy.

P273 EZETIMIBE/SIMVASTATIN 10/20 mg VERSUS ROSUVASTATIN 10 mg IN HIGH RISK HYPERCHOLESTEROLEMIC PATIENTS STRATIFIED BY PRIOR STATIN TREATMENT POTENCY

M. Viigimaa, L. Missault, P. Brudi, 2010 .

S. Kaplan, Arvind K. Shah, A. Meehan, 2006, The Journal of urology.

Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies

D. Bilheimer, T. Loeys, N. Chung, 2004, Current medical research and opinion.

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial

J. Tomassini, A. Adewale, S. Fazio, 2012, Diabetes Care.

Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.

C. Ballantyne, T. Pearson, E. Veltri, 2007, The American journal of cardiology.

Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?

Lawrence A Leiter, H. Bays, M. Hanson, 2010, Lipids in Health and Disease.

Elevated high sensitivity C-reactive protein levels in aging men with low testosterone

S. Kaplan, A. Johnson‐Levonas, Jianxin Lin, 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

W. Weintraub, D. Morrone, P. Toth, 2012, Atherosclerosis.

LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.

J. Mckenney, C. Ballantyne, W. Brady, 2005, MedGenMed : Medscape general medicine.

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

W. Hsueh, C. Ballantyne, J. Rosen, 2015, Lipids in Health and Disease.

Multivariate meta-analysis on correlation coefficients

T. Mathew, B. Sinha, Dihua Xu, 2013 .

Bootstrap Procedures for Testing Homogeneity Hypotheses

Bimal K. Sinha, Arvind Shah, Jianxin Lin, 2012 .

Meta-analysis and Cumulative Meta-analysis for Correlations: Methodology and Applications

T. Mathew, Dihua Xu, Jianxin Lin, 2011 .

Meta‐analysis methods and models with applications in evaluation of cholesterol‐lowering drugs

Joseph G Ibrahim, Ming-Hui Chen, Jianxin Lin, 2012, Statistics in medicine.

Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.

D. Tribble, M. Davidson, E. Veltri, 2006, Clinical therapeutics.

Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

H. Bays, Q. Dong, D. Maccubbin, 2012, American Journal of Cardiovascular Drugs.

Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial

S. Curtis, Arvind K. Shah, A. Melián, 2007, Current medical research and opinion.

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

L. Simons, B. Gumbiner, L. Masana, 2004, Current medical research and opinion.

Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.

M. Mercuri, E. Stein, H. Bays, 2002, The American journal of cardiology.

Bayesian network meta‐regression hierarchical models using heavy‐tailed multivariate random effects with covariate‐dependent variances

J. Ibrahim, Ming-Hui Chen, Hao Li, 2021, Statistics in medicine.

Bayesian flexible hierarchical skew heavy-tailed multivariate meta regression models for individual patient data with applications.

Ming-Hui Chen, Sungduk Kim, Joseph Ibrahim, 2020, Statistics and its interface.

Bayesian multivariate skew meta-regression models for individual patient data

Joseph G Ibrahim, Ming-Hui Chen, Sungduk Kim, 2018, Statistical methods in medical research.

Bayesian inference for multivariate meta‐analysis Box–Cox transformation models for individual patient data with applications to evaluation of cholesterol‐lowering drugs

Joseph G Ibrahim, Ming-Hui Chen, Sungduk Kim, 2013, Statistics in medicine.

Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes

Lawrence A Leiter, J. Guyton, P. Brudi, 2011, Diabetes & vascular disease research.

Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first two years of use?

I. Fraser, C. Vieira, A. Pong, 2019, Contraception.

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.

M. Viigimaa, L. Missault, P. Brudi, 2012, Cardiovascular therapeutics.

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.

C. Ballantyne, D. Hunninghake, B. Gumbiner, 2003, Clinical therapeutics.

Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65–74 and 75 years and older

Jennifer G. Robinson, J. Tomassini, M. Davidson, 2007 .

Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.

J. Tomassini, T. Mazzone, R. Goldberg, 2008, Journal of clinical lipidology.

ffect of ezetimibe / simvastatin vs atorvastatin on owering levels of LDL-C and non – HDLC , ApoB , and s-CRP in patients with type 2 diabetes

J. Tomassini, R. Goldberg, J. Guyton, 2008 .

Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.

B. Gumbiner, H. Bays, Arvind K. Shah, 2011, Metabolic syndrome and related disorders.

Efficacy and safety of ezetimibe/simvastatin co- administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome.

Jianxin Lin, Arvind K. Shah, Y. Mitchel, 2007, Metabolic syndrome and related disorders.

Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome.

D. Tribble, L. Ose, E. Veltri, 2007, Metabolic syndrome and related disorders.

Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis

D. Tribble, J. Rotonda, L. Ose, 2006, Current medical research and opinion.

Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.

J. Tomassini, O. Descamps, P. Brudi, 2015, Atherosclerosis.

Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.

J. Tomassini, E. Schaefer, R. Lowe, 2012, Atherosclerosis.

Long‐term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2‐year, open‐label extension study

D. Lütjohann, K. von Bergmann, T. Musliner, 2008, International journal of clinical practice.

Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20mg Compared with Rosuvastatin 10mg in High-Risk Patients with and Without Type 2 Diabetes Mellitus (T2DM)

M. Viigimaa, L. Missault, P. Brudi, 2009 .

Meta-analysis of HbA1c-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Combination with Insulin in T2DM Patients

Qing Tian, Jin Yang, T. Hong, 2018, Diabetes.

Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6–24 weeks

W. Weintraub, D. Morrone, P. Toth, 2012, International journal of clinical practice.

Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome

J. Tomassini, S. Fazio, J. Guyton, 2010, Diabetes, obesity & metabolism.

Jennifer G. Robinson, W. Hsueh, C. Ballantyne, 2013, Journal of clinical lipidology.

A multi‐centre, randomised, double‐blind 14‐week extension study examining the long‐term safety and efficacy profile of the ezetimibe/simvastatin combination tablet *

D. Tribble, T. Musliner, J. Lin, 2007, International journal of clinical practice.

Elevated high sensitivity C-reactive protein levels in aging men with low testosterone

S. Kaplan, Jianxin Lin, Arvind K. Shah, 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.